VOLUME-PRO niVOLUMab in the real world in patients with squamous cell carcinoma of the head & neck (SCCHN) – Patient Reported Outcomes (PRO). BMS-NIV-2020-01
COMMERCIAL POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: BRISTOL-MYERS SQUIBB COMPANY
- Execution start: 26/04/2021
- End of execution: 30/12/2022
- PI: JOAQUINA MARTINEZ GALAN